- Home
- AUPH vs PHVS Comparison
AUPH vs PHVS Comparison
Compare AUPH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- PHVS
- Stock Information
- Founded
- AUPH 1993
- PHVS 2015
- Country
- AUPH Canada
- PHVS Switzerland
- Employees
- AUPH N/A
- PHVS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- PHVS Health Care
- Exchange
- AUPH Nasdaq
- PHVS Nasdaq
- Market Cap
- AUPH 1.4B
- PHVS 1.3B
- IPO Year
- AUPH 1999
- PHVS 2021
- Fundamental
- Price
- AUPH $12.22
- PHVS $23.25
- Analyst Decision
- AUPH Strong Buy
- PHVS Strong Buy
- Analyst Count
- AUPH 4
- PHVS 5
- Target Price
- AUPH $12.25
- PHVS $35.60
- AVG Volume (30 Days)
- AUPH 1.7M
- PHVS 129.1K
- Earning Date
- AUPH 11-06-2025
- PHVS 08-12-2025
- Dividend Yield
- AUPH N/A
- PHVS N/A
- EPS Growth
- AUPH N/A
- PHVS N/A
- EPS
- AUPH 0.42
- PHVS N/A
- Revenue
- AUPH $260,111,000.00
- PHVS N/A
- Revenue This Year
- AUPH $16.92
- PHVS N/A
- Revenue Next Year
- AUPH $14.29
- PHVS N/A
- P/E Ratio
- AUPH $29.10
- PHVS N/A
- Revenue Growth
- AUPH 25.59
- PHVS N/A
- 52 Week Low
- AUPH $6.42
- PHVS $11.51
- 52 Week High
- AUPH $12.82
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AUPH 61.79
- PHVS 54.92
- Support Level
- AUPH $11.57
- PHVS $21.50
- Resistance Level
- AUPH $12.82
- PHVS $24.52
- Average True Range (ATR)
- AUPH 0.36
- PHVS 1.50
- MACD
- AUPH -0.10
- PHVS -0.05
- Stochastic Oscillator
- AUPH 52.08
- PHVS 52.76
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.